NCT07192211View on ClinicalTrials.gov

Exploratory Study of ADR-002K for Heart Failure Patients With Ischemic Heart Disease Who Undergo CABG

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

50

Participants

Timeline

Start Date

September 30, 2025

Primary Completion Date

September 30, 2028

Study Completion Date

March 31, 2029

Conditions

Ischemic Heart Disease

Interventions

BIOLOGICAL

Mesenchymal stem cell

ADR-002K administration

BIOLOGICAL

Placebo

Placebo

All Listed Sponsors

lead

Rohto Pharmaceutical Co., Ltd.

INDUSTRY